Status:
UNKNOWN
Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe
Lead Sponsor:
Pitié-Salpêtrière Hospital
Collaborating Sponsors:
Università degli Studi di Ferrara
Rheumazentrum Ruhrgebiet
Conditions:
COVID-19
Systemic Lupus Erythematosus
Eligibility:
All Genders
18+ years
Brief Summary
The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern. In European countries such as Spain, Italy, Germany, Portugal, Eng...
Eligibility Criteria
Inclusion
- Age \> 18 years;
- Patients fitting classification criteria for each IMID (i.e., Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, axial spondyloarthritis or giant cell arteritis);
- Willingness to participate;
- There are no specific inclusion criteria based on IMID previous activity, treatment or known COVID-19.
Exclusion
- Patients who refuse to participate;
- Patients who don't speak or read the local language,
- Patients unable to perform a routine blood collection during the study period
Key Trial Info
Start Date :
June 10 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2021
Estimated Enrollment :
3100 Patients enrolled
Trial Details
Trial ID
NCT04397237
Start Date
June 10 2020
End Date
January 1 2021
Last Update
December 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saadoun
Paris, Île-de-France Region, France, 75013